Featured Program
Featured Resources
Featured Advocacy Letters
NCL Sends Letter to Senate HELP Committee on Lowering Healthcare Costs
/in Featured Home - Health/by allisoncAugust 1, 2025: Washington, DC – On July 31, 2025, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on the rising cost of healthcare and the urgent need for patient-focused reform. Lawmakers and expert witnesses discussed challenges with employer-sponsored insurance, the lack of price transparency, and the profit-driven nature of the U.S. healthcare system.
Featured Press Releases
New Report: 340B Cancer Hospitals More Likely to Pursue Aggressive Medical Debt Collection
/in Featured Home - Health/by Lisa McDonaldMarch 2, 2025: Washington, DC – A new analysis from the National Consumers League (NCL) finds that hospitals participating in the federal 340B Drug Pricing Program—including many hospitals that treat high volumes of cancer patients —are more likely than non-340B hospitals to permit aggressive medical debt collection practices such as lawsuits, wage garnishment, liens, and credit reporting.
Top Ten Scams Report: Phishing and Spoofing Scams Nearly Double in 2025 as AI-Powered Fraud Surges
/in Featured Home - Fraud Prevention/by Lisa McDonaldMarch 2, 2026: Washington, DC – Phishing and spoofing scams soared by 85.6% over the past year, doubling median losses from $1,000 to $2,060, according to the National Consumers League’s Fraud.org Top Ten Scams of 2025 report. Of 1,376 consumer complaints analyzed, investment scams caused the highest median loss at $30,000.
National Consumers League Commends FDA for Swift Action Against Hims & Hers
/in Featured Home - Food, Nutrition, & Obesity/by Lisa McDonaldFebruary 9, 2026: Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food and Drug Administration announced it would stop the telehealth platform Hims & Hers from marketing a compounded version of the first FDA-approved GLP-1 weight-loss pill. On Saturday, Hims & Hers said it was withdrawing the product from the market, and the FDA did not pursue enforcement action.
NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs
/in Featured Home - Food, Nutrition, & Obesity/by allisoncFebruary 4, 2026: Washington, DC – A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems. The purpose was to inform consumers about the potential harm posed by these drugs before Hims & Hers, a large telehealth company, aired a widely hyped television ad during the 2025 Super Bowl touting only the benefits of compounded GLP-1s.